Brief: Parnell Pharmaceuticals announces positive top-line pivotal trial results for Zydax(R), disease-modifying osteoarthritis drug in dogs
18/06/2015 12:01
June 18 (Reuters) - Parnell Pharmaceuticals Holdings Ltd PARN.O : * Announces positive top-line pivotal trial results for Zydax, disease-modifying osteoarthritis drug in dogs * Says primary end-point for the trial was a reduction of 3 or more in the activity impairment score * Says zydax showed significant improvement in clinical signs of osteoarthritis in dogs in pivotal efficacy trial * Source text for Eikon ID:nGNXVDVKZa * Further company coverage PARN.O ((Bengaluru Newsroom; +1 646 223 8780))
Recent news on Parnell Pharmaceuticals Holdings
See all newsBrief: Parnell Pharmaceuticals announces intention to move from Nasdaq OMX global market
Brief: Parnell Pharmaceuticals sees FY 2016 revenue of $14 million to $16 million
Brief: Parnell Pharmaceuticals says manufacturing deal with Merial
Brief: Parnell Pharmaceuticals announces pricing of underwritten public offering
Brief: Parnell Pharmaceuticals Q1 revenue rose 43 percent to $2.2 mln